Vector, genetically transformed actinomycete, method for producing protein, and promoter
Novel promoters in actinomycetes, such as pmi and phpR, enhance gene expression, addressing the inefficiencies of existing promoters and increasing protein production in actinomycetes.
Patent Information
- Application Number
- JP2023073970
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-04-28
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing promoters used in actinomycetes do not efficiently express target genes, leading to suboptimal production of desired secondary metabolites.
Identification and utilization of novel promoter regions, specifically the pmi promoter (SEQ ID NO: 1), phpR promoter (SEQ ID NO: 2), and a promoter derived from Streptomyces viridochromogenes (SEQ ID NO: 3), which exhibit high expression levels in actinomycete cells, allowing for enhanced production of target proteins.
The novel promoters enable high-efficiency expression of target genes in actinomycetes, resulting in increased production of target proteins.
Smart Images

Figure 2024158618000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to gene recombination technology using actinomycetes. [Background technology]
[0002] Many of the secondary metabolites produced by microorganisms such as actinomycetes have physiological activity and are used in our daily lives as antibiotics and the like (Non-Patent Document 1). In general, naturally occurring microbial strains have low productivity of the target secondary metabolites, so breeding has been carried out to improve productivity. Conventional breeding methods mainly involve providing a mutagen and selecting a strain with increased productivity of the target product, but in recent years, many attempts have been made to improve the productivity of the target product using gene recombination technology.
[0003] In order to express a foreign gene in a genetically modified microorganism, the foreign gene must be linked to a transcription promoter and introduced into the microorganism. Since the level of gene expression varies greatly depending on the choice of this promoter, the choice of transcription promoter is extremely important.
[0004] For example, examples of highly expressing promoters that are widely used in recombinant actinomycetes include the SF14 promoter (Non-Patent Document 2), the ermEp promoter (Non-Patent Document 3, Patent Document 1), and the kasO promoter. (Non-Patent Document 4, Patent Document 2) and the like are known. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] China Patent Application Publication No. 105420266 [Patent Document 2] China Patent Application Publication No. 103421778 [Non-patent literature]
[0006] [Non-Patent Document 1] Lacey et al., Molecules, 2022, 27, 887 [Non-Patent Document 2] Labes et al., Microbiology, 1997, 143, 1503-1512 [Non-Patent Document 3] Bibb et al., Gene, 1985, 38, 215-226 [Non-Patent Document 4] Wang et al., Applied and Environmental Microbiology, 2013, 79, 4484-4492 Summary of the Invention [Problem to be solved by the invention]
[0007] As described above, promoters that can function in actinomycete host cells are known. However, depending on the species of actinomycete, the known promoters may not be able to achieve high expression of a target gene, such as a foreign gene, and therefore there is a demand for promoters that can express a target gene more efficiently. Therefore, an objective of the present invention is to provide a technique for improving the expression level of a target gene in actinomycete cells and producing a large amount of a target protein. [Means for solving the problem]
[0008] As a result of intensive research conducted by the present inventors to solve the above problems, they discovered that a specific promoter region possessed by actinomycetes can highly express a target gene such as a foreign gene, compared to the case of using a known promoter that is widely used in recombinant actinomycetes, and thus completed the present invention. In addition, they selected promoter candidates for expressing a target gene in actinomycete cells by transcriptome analysis, and found a novel promoter region capable of highly expressing a target gene from among the promoter candidates, thereby completing the present invention.
[0009] The present invention provides the following: [1] A vector comprising a gene of interest operably linked to a promoter, The promoter is a polynucleotide having the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or A vector comprising a polynucleotide which hybridizes under stringent conditions with a polynucleotide having a complementary sequence to the base sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 and has promoter activity in actinomycete cells. [2] The vector described in [1], wherein the polynucleotide having promoter activity is a polynucleotide having a base sequence having 90% or more identity to the base sequence of SEQ ID NO: 1, a base sequence having 90% or more identity to the base sequence of SEQ ID NO: 2, or a base sequence having 90% or more identity to the base sequence of SEQ ID NO: 3. [3] A transformed actinomycete transformed with the vector according to [1] or [2]. [4] Streptomyces ( Streptomyces The transformed actinomycete according to [3], which is a bacterium of the genus Actinomyces. [5] The above-mentioned Streptomyces ( Streptomyces ) bacteria is Streptomyces viridochromogenes ( Streptomyces viridochromogenes ) The transformed actinomycete described in [4]. [6] The transformed actinomycete according to any one of [3] to [5], wherein the target gene is a foreign gene. [7] A method for producing a protein, comprising culturing the transformed actinomycete according to any one of [3] to [6] and allowing the transformed actinomycete to accumulate a protein encoded by a gene of interest. [8] A polynucleotide having the nucleotide sequence of SEQ ID NO: 3, or A promoter comprising a polynucleotide which hybridizes under stringent conditions with a polynucleotide having a complementary sequence to the base sequence of SEQ ID NO: 3 and has promoter activity in actinomycete cells. Effect of the Invention
[0010] According to the present invention, a target gene can be expressed with high efficiency in actinomycete cells, and a large amount of a target protein can be produced. [Brief description of the drawings]
[0011]
Figure 1
Figure 2
[0012] In this specification, the accession numbers of strains beginning with the word JCM are those of the Japan Collection of Microorganisms (RIKEN BioResource Center, Microbial Materials Research Center). Microorganisms stored in the Laboratory of Microorganisms (Hokkaido University, Tsukuba City, Ibaraki Prefecture, Japan, Postal Code: 305-0074, Address: 3-1-1 Takanodai, Tsukuba City, Ibaraki Prefecture) The number is assigned to the organization and is available from the organization.
[0013] In this specification, the strains with the accession numbers beginning with the word ATCC are registered trademarks of the American Type Culture Collection (Address: 10801 Univ. For more information, please contact the National Institute of Standards and Technology (NIS) at 1-800-230-4500, or call 1-800-230-4500, Fax ...
[0014] In this specification, the strains with accession numbers beginning with the words NBRC are registered trademarks of the National Institute of Technology and Evaluation (NITE) (Postal Code: 292-0818, Address: 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan). This is a number given to microorganisms stored in the National Institute of Informatics (NII) and can be obtained from the Institute.
[0015] Streptomyces viridochromogenes ( Streptomyces viridochromogenes Streptomyces viridochromogenes is a type of actinomycete that produces the nonselective herbicide bialaphos. It is known that Streptomyces viridochromogenes has a bialaphos synthase gene cluster, which contains multiple promoter regions. The inventors have newly discovered that a specific promoter region among these multiple promoter regions is useful for improving the expression level of a target gene, such as an exogenous gene, and can achieve higher expression of the target gene than when a known promoter commonly used in genetically modified actinomycetes is used.
[0016] The vector of the present invention is a vector comprising a gene of interest linked to a promoter in an expressible manner, wherein the promoter comprises a polynucleotide that hybridizes under stringent conditions with a polynucleotide having the base sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, or a polynucleotide having a complementary sequence to the base sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, and has promoter activity in actinomycete cells.
[0017] The base sequence of SEQ ID NO:1 is derived from Streptomyces viridochromogenes ( S. viridochromogenesThe entire base sequence of the promoter (pmi promoter) located upstream of the pmi gene (GenBank accession number: AY632421.1) in the bialaphos synthase gene cluster of It is an array.
[0018] The nucleotide sequence of SEQ ID NO: 2 is the entire nucleotide sequence of a promoter (phpR promoter) located upstream of the transcriptional regulator phpR (GenBank accession number: AY632421.1) in the bialaphos synthase gene cluster of Streptomyces viridochromogenes.
[0019] In addition, the present inventors have found a novel promoter that can have promoter activity useful for improving the expression level of a target gene in actinomycete cells by transcriptome analysis of Streptomyces viridochromogenes. The nucleotide sequence of SEQ ID NO: 3 is the entire nucleotide sequence of this novel promoter, and is a protein sequence of GenBank accession number WP_003988467.1. It is the upstream region of the gene encoding
[0020] "Stringent conditions" refer to conditions under which so-called specific hybrids are formed and non-specific hybrids are not formed. For example, two DNAs with high identity, preferably two DNAs with an identity of 80% or more, more preferably 90% or more, particularly preferably 95% or more, hybridize with each other, but two DNAs with lower identity do not hybridize. For example, the conditions include conditions under which the hybridization is performed once, preferably twice to 3 times, at a salt concentration and temperature corresponding to 60°C, 0.1×SSC, 0.1% SDS, more preferably 68°C, 0.1×SSC, 0.1% SDS. That is, the promoter contained in the vector of the present invention may have a nucleotide sequence that has 80% or more, more preferably 90% or more, and particularly preferably 95% or more identity to the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, as long as it has promoter activity in actinomycete cells.
[0021] Furthermore, the promoter may have a nucleotide sequence containing one or several nucleotide substitutions, deletions, insertions or additions in the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, so long as it has promoter activity in actinomycete cells. Here, one or several means, for example, 1 to 50, 1 to 30, 1 to 10, or 1 to 5. The promoter contained in the vector of the present invention may be a partial sequence in which the 5'-end and / or 3'-end of the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 has been deleted, so long as it has promoter activity in actinomycete cells.
[0022] The promoter activity can be detected by linking a target gene to the 3'-terminus of the promoter sequence, introducing it into actinomycete cells as host cells, and examining the expression of the target gene.
[0023] The target protein can be expressed in a host cell by linking a gene encoding the target protein (target gene) to the promoter of the present invention in an expressible state and introducing the gene into the host cell using a vector, etc. The target gene is not particularly limited as long as it can be expressed in the host cell, but is preferably a foreign gene.
[0024] The type of target protein is not particularly limited as long as it can be expressed in a host cell, and examples of the target protein include growth factors, hormones, cytokines, blood proteins, enzymes, antigens, antibodies, transcription factors, receptors, or partial peptides thereof. The origin of the protein is not particularly limited, and may be, for example, derived from mammals such as humans, plants, bacteria, or yeasts.
[0025] Examples of the enzyme include antibiotic synthesis enzymes, lipases, proteases, steroid synthesis enzymes, kinases, phosphatases, methylases, demethylases, oxidases, reductases, cellulases, aromatases, collagenases, transglutaminase, glycosidases, and chitinases.
[0026] Examples of antibiotic synthases include bialaphos synthase (Blodgett et al. 2016, J Antibiot (Tokyo). 69, 15-25), L-glufosinate synthase, and dehydrophos synthase. (Circello BT et al., 2010. Chemistry & Biology 17, 402-411), Phosphomycin FR900098 synthase (Kim SY et al., 2012. Antimicrobial Agents and Chemotherapy 56, 4175-4183), and FR900098 synthase (Eliot AC et al., 2012, Chem Biol. 15, 765-770). Some examples include:
[0027] Examples of growth factors include epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage-derived stimulating factor (G-CSF), and granulocyte macrophage-derived stimulating factor (G-CSF). These include phage colony-stimulating factor (GM-CSF), platelet-derived growth factor (PDGF), erythropoietin (EPO), thrombopoietin (TPO), fibroblast growth factor (FGF), and hepatocyte growth factor (HGF).
[0028] Examples of hormones include insulin, glucagon, somatostatin, growth hormone, parathyroid hormone, prolactin, leptin, and calcitonin.
[0029] Examples of cytokines include interleukins, interferons (IFNα, IFNβ, IFNγ), and tumor necrosis factors (TNF).
[0030] Examples of blood proteins include thrombin, serum albumin, factor VII, factor VIII, factor IX, factor X, tissue plasminogen activator, and the like.
[0031] Antibodies include, for example, complete antibodies, Fab, F(ab'), F(ab')2, Fc, and Fc fusion proteins. Examples of Fv include Fv proteins, heavy chains (H chains), light chains (L chains), single-chain Fvs (scFvs), sc(Fv)2, disulfide-linked Fvs (sdFvs), and diabodies.
[0032] The antigen protein used as a vaccine is not particularly limited as long as it can induce an immune response, and may be appropriately selected depending on the target of the anticipated immune response. Examples of the antigen protein include proteins derived from pathogenic bacteria and proteins derived from pathogenic viruses.
[0033] The target protein may be added with a secretory signal peptide that functions in a host cell for secretory production. Examples of the secretory signal peptide include secretory signals for xylanase, subtilisin protease inhibitor, phospholipase D, endoglucanase, laccase, chitinase, alkaline phosphatase, etc.
[0034] Furthermore, a transport signal peptide such as an endoplasmic reticulum retention signal peptide or a vacuolar targeting signal peptide may be added to the target protein in order to express the protein in a specific cellular compartment, and a tag sequence such as a His tag, a FLAG tag, or a GST tag may be added to the target protein for the purpose of detection or purification.
[0035] The DNA encoding the target protein (target gene) is, for example, a gene encoding the target protein based on a known base sequence. The target protein can be obtained by a general genetic engineering technique. In addition, the amount of the protein translated from the DNA encoding the target protein increases depending on the host cell in which the protein is produced. Codons representing amino acids constituting the protein may be appropriately modified so as to modify the codons. For example, the method of Kang et al. (Protein Expr Purif. 2004 Nov;38(1):129-35.) can be used as a reference for the codon modification method. Other examples include a method of selecting codons that are frequently used in host cells, selecting codons with a high GC content, or selecting codons that are frequently used in housekeeping genes of the host cells.
[0036] In addition, in order to improve gene expression in host cells, it is necessary to add a ribosome binding site (RBS) that functions as a recognition sequence for translation initiation in host cells. The RBS is not particularly restricted in sequence as long as it has the translation initiation function. Although not a direct copy, the sequences disclosed in, for example, Bai et al., 2015, PNAS 112, 12181-12186 can be used. Can be used.
[0037] The promoter contained in the vector of the present invention and the recombinant DNA containing it are For example, the DNA encoding the promoter contained in the vector of the present invention can be obtained from actinomycete genomic DNA or the like by a technique such as PCR, and a useful promoter can be obtained. The promoter is created by linking the DNA encoding the protein using PCR or DNA ligase. It is possible to construct recombinant DNA comprising the gene.
[0038] The vector of the present invention contains a promoter as described above and is used to express a gene of interest in a host cell. The vector of the present invention preferably contains a gene of interest as described above. If necessary, a terminator sequence can also be included depending on the host cell. The vector may also contain a selection marker such as a drug resistance gene.
[0039] The expression vector used to prepare the vector of the present invention is not particularly limited as long as it can be replicated and propagated in the host cell, actinomycete, and examples of the expression vector include plasmid vectors and shuttle vectors.
[0040] Plasmid vectors include pGM1190, pSET152, pKC1139, SCP2, SLP1.2, and pIJ101. Examples of plasmid vectors that can replicate autonomously within cells include:
[0041] The vector of the present invention can be prepared by, for example, cleaving the promoter of the present invention, preferably the promoter of the present invention and a gene of interest linked thereto, with an appropriate restriction enzyme or by isolating the gene at a restriction enzyme site by PCR. The gene can be prepared by adding a restriction site and inserting the gene into a restriction enzyme site or a multicloning site of a vector.
[0042] The transformed actinomycete of the present invention is characterized in that it is transformed with the vector described above. The host cell used for transformation is not particularly limited as long as it is an actinomycete. For example, Streptomyces viridomogenes ( Streptomyces viridochromogenes ), Streptomyces lividans ( Streptomyces lividans ), Streptomyces coelicolor -( Streptomyces coelicolor ), Streptomyces kanamyceticus ( Streptomyces kanamyceticus ) and other Streptomyces ( Streptomyces ) bacteria; Saccharopolis Pola spinosa (S accharopolyspora spinosa ), Saccharopolyspora erythrea (S accharopolyspora erythraea ) and other Saccharopolyspora ( Saccharopolyspora ) bacteria Examples include Streptomyces ( Streptomyces ) bacteria are preferred, and Streptomyces viridochromogenes is more preferred.
[0043] Streptomyces viridochromogenes includes the JCM4977 and Tue57 strains (Weitnauer, G. et al., (2002). Microbiology, 148(2), 373-379.), subsp. Komabensis (ATCC29814 strain), and subsp. sulfomycini (NBRC13830). Stocks, etc.
[0044] The transformed actinomycete of the present invention (also referred to as a transformant) can be prepared by introducing the vector of the present invention into a host cell using a general genetic engineering technique. For example, electroporation (Tada et al., 1990, Theor. Appl. Genet, 80: 475), conjugal transfer (Flett et al., 1997, FEMS Microbiol. Lett, 155: 223-229), protoplast method (Gene, 39, 281-286 (1985)), polyethylene glycol method (Lazzeri et al., 1991, Theor. Appl. Genet. 81: 437), introduction method using Agrobacterium (Hood et al., 1993, Transgenic, Res. 2: 218, Hiei et al., 1994 Plant J. 6: 271), particle gun method (Sanford et al., 1987, J. Part. Sci.tech. 5: 27) and the polycation method (Ohtsuki, et al., FEBS Lett. 1998 May 29;428(3):235-40.) The gene expression may be either transient expression or stable expression in which the gene is integrated into a chromosome.
[0045] After the vector of the present invention is introduced into a host cell, a transformant can be selected using the phenotype of the selection marker as an index. The selected transformant can be cultured to produce a protein. The medium and conditions used for culture can be appropriately selected depending on the species of the transformant.
[0046] The target protein accumulated in the medium or cells can be separated and purified according to methods well known to those skilled in the art, for example, salting out, ethanol precipitation, ultrafiltration, gel filtration chromatography, ion exchange column chromatography, affinity chromatography, medium to high pressure liquid chromatography, reversed phase chromatography, hydrophobic chromatography, or other known appropriate methods, or a combination of these. EXAMPLES
[0047] Examples of the present invention will be described below, but the present invention is not limited to these examples.
[0048] [Example 1: Comparison of Fluc activity between pmi promoter and phpR promoter] In Example 1, fireflies ( Photinus pyralis The luciferase (Fluc) derived from the .alpha.- 10-mer gene was used as a reporter protein, and the protein expression was regulated by the pmi promoter and the phpR promoter. The above effects were examined.
[0049] (1) Synthesis of promoter Fragments of the pmi promoter (SEQ ID NO: 1) and the phpR promoter (SEQ ID NO: 2), respectively The fragments were designed to add an NsiI site to the 5' end and an AatII site to the 3' end of each fragment. The gene was then chemically synthesized using FASMAC's artificial gene synthesis service.
[0050] The NsiI-AatII fragments of each known promoter were obtained by the following procedure. For comparison, the known promoter Streptomyces coelicolor ( Streptomyces coelicolor ) kasO promoter, Streptomyces ganaensis ( Streptomyces ghanaensis ) and the SF14 promoter of Streptomyces erythraea ( Streptomyces erythraeus The ermEp promoter of the kasO promoter (SEQ ID NO: 5), the SF14 promoter (SEQ ID NO: 6) and the ermEp promoter (SEQ ID NO: 7), respectively, were used. The base sequence was submitted to the GenBank database (www.ncbi.nlm.nih.gov / genbank / ). The base sequences of SEQ ID NOs: 5 to 7 were each chemically synthesized using the artificial gene synthesis service provided by FASMAC Corporation. Each of the chemically synthesized base sequences was cleaved with NsiI-AatII and purified.
[0051] (2) Preparation of plasmids Using the following procedure, each The promoter fragment and firefly ( Photinus pyralis ) was linked to a luciferase (Fluc) (SEQ ID NO: 4) reporter derived from
[0052] First, pSET152 was cleaved with HindIII-EcoRV, and phosphorylated oligonucleotide A (SEQ ID NO: 8) and phosphorylated oligonucleotide B (SEQ ID NO: 9) were annealed and then ligated. By inserting the nucleotide sequence into the DNA, the XbaI and NsiI sites were introduced. As a result, the XbaI-NsiI fragment of pSET152 was obtained.
[0053] Next, the rrnB terminator (SEQ ID NO: 10) was fused to Fluc (SEQ ID NO: 4). Photinus pyralisFluc derived from was prepared by PCR using Fluc-HSPT (Matsui et al., 2015, Plant Biotech 32, 309-16) as a template and Fluc-F primer (SEQ ID NO: 13) and Fluc-R primer (SEQ ID NO: 14). Next, two types of oligo DNA, rrnB-F (SEQ ID NO: 11) and rrnB-R (SEQ ID NO: 12), were mixed and incubated in hot water, and then allowed to stand at room temperature for annealing. Double-stranded DNA corresponding to the rrnB terminator was synthesized by T4 DNA polymerase treatment. Then, Fluc and the rrnB terminator were inserted via SacI. The rrnB terminator was ligated and the resulting fragment was digested with AatII and SpeI to obtain the rrnB terminator. The AatII-SpeI fragment of Fluc fused with TAGAGA was obtained.
[0054] Plasmids in which each promoter was linked to luciferase were constructed by three-way ligation of the NsiI-AatII fragment of each promoter, the AatII-SpeI fragment of Fluc fused with the rrnB terminator, and the XbaI-NsiI fragment of pSET152.
[0055] [Table 1] In the table, the sequences are oriented from left to right from 5' to 3' end.
[0056] The base sequences of the primers used are shown in Table 2.
[0057] [Table 2] In the table, the sequences are oriented from left to right from 5' to 3' end.
[0058] (3) Transformation of E. coli for conjugation Each of the constructed plasmids was used to transform E. coli by electroporation according to the following procedure. First, competent cells of the E. coli S17-1 strain were prepared by the following procedure. Streaking the glycerol stock of E. coli S17-1 on an LB plate, then incubating at 37°C for 16-20 hours. A single colony was obtained by inoculating the single colony into 2.5 mL of LB medium and incubated at 37 °C. The mixture was pre-cultured at 37°C, 200 rpm for 16 hours. 200 μl of the pre-culture was inoculated into 20 mL of LB medium and incubated at 37°C, 200 rpm for 16 hours at OD 600 The bacteria were harvested by centrifugation (4°C, 3000 xg, 10 min). Then, discard the supernatant, add 20 mL of ice-cold sterile water, and gently suspend the pellet with a pipette. After repeating the steps of collecting and washing the bacteria once more, the bacteria were collected again by centrifugation (4°C, 3000 xg, 10 min), the supernatant was discarded, and the pellet was gently suspended in 200 μl of ice-cold 10% glycerol using a pipette. 50 μl of this suspension was added to each tube (Eppendorf tube). Competent cells of the S17-1 strain were prepared by dispensing the cells into a culture flask (manufactured by Eppendorf).
[0059] The constructed plasmid (~2 μL) was added to the prepared competent cells and electroporated. The cells were transferred to a poration cell (Bio-Rad Laboratories, Inc.) and then left to stand on ice for 10 minutes. An electric pulse of 1.8 kV, 25 μF, and 200 Ω was applied, and 1 mL of LB medium was added. The bacteria were then harvested at 20,000 xg for 1 minute, the supernatant was removed, and the bacteria were resuspended in an appropriate amount of medium, spread on 2xYT agar medium containing 50 μg / mL apramycin, and cultured overnight at 37°C. In addition, the same procedure was carried out except that an empty vector (pSET152) was used instead of the constructed plasmid. Escherichia coli was transformed and cultured according to the procedure of 1. above, and this was used as a negative control.
[0060] (4) Preparation of transformed actinomycetes Using the transformed E. coli, actinomycetes were transformed by conjugal transfer according to the following procedure. The E. coli S17-1 strain carrying the transformation plasmid obtained by the above culture was inoculated into 2 mL of LB medium containing 50 μg / mL apramycin and precultured overnight at 37°C and 200 rpm. 100 μL of the preculture was inoculated into 10 mL of fresh LB medium (containing 50 μg / mL apramycin) and the OD 600 The cells were cultured at 37°C and 200 rpm until the pH reached 0.4-0.8. The cells were harvested at 8000 xg for 10 minutes, the supernatant was discarded, and the harvested cells were suspended (washed) in 10 mL of LB medium by pipetting. The washing process was repeated twice to remove antibiotics contained in the culture medium. The collected bacterial pellet was then resuspended in 1 mL of LB medium. 500 μL of this E. coli suspension was then added to the same The cells were suspended in 500 μl of 2×YT medium, heat-shocked at 50°C for 10 minutes, and then left on ice. Streptomyces viridochromogenes ( S. viridochromogenes )JCM4977 The spores were mixed with the strain spores and centrifuged briefly. Ten, 1% by weight starch, 0.2% by weight calcium carbonate, 0.2% by weight ammonium sulfate, 0.1% by weight dipotassium hydrogen phosphate, 0.1% by weight magnesium sulfate heptahydrate, 0.1% by weight sodium chloride Thorium, 0.1% by weight Yeast extract, 0.0001% by weight Iron(II) sulfate heptahydrate, 0.0001% by weight The actinomycetes were plated on a mixture of manganese chloride heptahydrate and 0.0001 wt% zinc sulfate heptahydrate and cultured at 28°C for approximately two weeks to obtain the culture medium. After the above centrifugation, the supernatant was discarded, leaving about 50 μL, and the bacterial pellet was resuspended in the remaining supernatant, after which a dilution series was prepared with sterile water, and 100 μL was applied to 20 ml of ISP4 plate medium and cultured overnight at 28°C. 0.5 mg of nalidixic acid and an antibiotic solution (20 μl of 50 mg / mL apramycin) were added to 1 ml of sterile water, which was then layered on the medium and cultured at 28°C for an additional 3 to 5 days to obtain actinomycete transformants.
[0061] (5) Cultivation of transformants The obtained transformants were each cultured in YS medium containing 50 mg / L apramycin (1% by weight soluble starch, 0.2% by weight yeast extract) in a 500 ml baffled flask The bacteria were inoculated onto the medium and pre-cultured at 140 rpm and 28°C for 3 days. MYG medium (1% by weight malt extract, 0.4% by weight yeast extract, 0.4% by weight glucose ) was inoculated into a 500-ml baffled flask containing 150 ml of the culture medium and cultured at 28°C at 140 rpm until the third day and at 85 rpm thereafter.
[0062] (6) Measurement of luciferase luminescence After centrifugation of 2 ml of the culture medium on the 6th day at 15,000 rpm for 15 minutes, the supernatant was removed and the cells were harvested. The cells were then soaked in glass beads (BM Equipment, 0.5 mm glass beads, Cat. No. 15-340-152). ), and then Passive lysis buffer was added, followed by vibration disruption by reciprocal shaking at 25 times / second for 1 minute using a Tissue Lyser II (Qiagen). After centrifugation at 15,000 rpm and 4°C for 15 minutes, the supernatant was collected. The amount of luminescence from luciferase was measured using the collected supernatant and ONE-Glo™ Luciferase Assay System (Promega, No. E8130). Protein concentration was also measured by the Bradford method, and the amount of luminescence from luciferase per unit protein was calculated. The results are shown in Figure 1.
[0063] (7) Results When the pmi promoter and phpR promoter are used, high expression is possible in actinomycetes. Three promoters that have been reported to be involved in the The luciferase activity was higher in the kasO promoter than in the kasO promoter (Fig. 1). In the kasO promoter, the luciferase activity was below the detection limit (data not shown). ).
[0064] [Example 2: Transcriptome analysis and comparison of Fluc activity of promoter candidates] To obtain further high-expression promoters, we performed transcriptome analysis on culture samples of actinomycetes, selected high-expression promoter candidates from the analysis results, and used them to express the promoters in firefly ( Photinus pyralis The effect of promoter candidates on enhancing protein expression was examined using luciferase (Fluc) derived from Escherichia coli ) as a reporter protein.
[0065] (1) Transcriptome analysis Streptomyces viridochromogenes ( Streptomyces viridochromogenes ) RNA was extracted from the JCM4977 strain and sequenced. As a result, the expression data of approximately 7,000 genes were obtained. The data was obtained. Based on the obtained expression data, we identified high-expression promoter candidate genes (GenBank accession The upstream regions of the genes encoding proteins with the following sequence numbers were selected as promoter candidates: WP_003988028.1, WP_003991794.1, WP_003988467.1, and WP_039931923.1.
[0066] (2) Construction of promoter-linked luciferase [Construction of pmi promoter-linked Fluc and preparation of plasmid] First, an autonomously replicating plasmid (pGH) was constructed by replacing the apramycin resistance gene of pGM1190 (addgene, #69994) with a hygromycin resistance gene. Specifically, inverse PCR was performed using pGM1190 as a template and I-44 primer (sequence number 20) and I-45 primer (sequence number 21) to create an apramycin resistance gene to replace the drug resistance marker. The resulting DNA fragment was digested with NsiI and SpeI while deleting the functional gene. The plasmid was digested with SpeI and the NsiI-NheI fragment of the hygromycin resistance gene was inserted. The hygromycin resistance gene was amplified by PCR using the I-17 primer (sequence number 22) and I-47 primer (sequence number 23) with the hygromycin resistance gene fragment (sequence number 15) chemically synthesized by FASMAC using their artificial gene synthesis service as a template. It was produced by the following.
[0067] As a positive control, a pmi promoter-linked Fluc was constructed. To compare transcriptional activity, the eight bases upstream from the start codon ATG, including the SD sequence, were replaced with a sequence (GGTACCGCGAATG, where ATG represents the start codon) common to other candidate promoters shown later. This was also the case for amplifying other candidate promoter fragments shown later. Specifically, Streptomyces viridochromogenes (S. viridochromogenes The genomic DNA of the JCM4977 strain was used as a template, and the I-48 primer (SEQ ID NO: 24) and I-49 primer (SEQ ID NO: 25) were used to amplify the The pmi promoter fragment was amplified by PCR using the sequence shown in column 25).
[0068] In addition, pSET152 was used as a template, and I-54 primer (SEQ ID NO: 26) and I-55 primer (SEQ ID NO: 27) were used. The transcription terminator region (SEQ ID NO: 16) was amplified by PCR using the .
[0069] Firefly ( Photinus pyralis ) genome as a template, and Fluc (SEQ ID NO: 4) was amplified by PCR using I-61 primer (SEQ ID NO: 28) and I-62 primer (SEQ ID NO: 29). .
[0070] The amplified EcoRI-KpnI fragment of the pmi promoter, the KpnI-SpeI fragment of Fluc, and the XbaI-HindIII fragment of the transcription terminator region were inserted into the EcoRI-HindIII gap of pGH to construct the pmi promoter. A plasmid was constructed into which the motor, Fluc, and transcription terminator regions were inserted.
[0071] [Construction of candidate promoter-linked Fluc and preparation of plasmid] As a candidate promoter, Streptomyces viridochromogenes ( S. viridochromogenesUsing the genomic DNA of the JCM4977 strain as a template, the upstream region of the gene encoding the protein of GenBank accession numbers WP_003988028.1 (SEQ ID NO: 17), the upstream region of the gene encoding the protein of WP_003991794.1 (SEQ ID NO: 18), the upstream region of the gene encoding the protein of WP_003988467.1 (SEQ ID NO: 3), and the upstream region of the gene encoding the protein of WP_039931923.1 (SEQ ID NO: 19) were amplified by PCR. The primers used were I-63 primer (SEQ ID NO: 30) and I-64 primer (SEQ ID NO: 31), I-65 primer (SEQ ID NO: 32) and I-66 primer (SEQ ID NO: 33), I-67 primer (SEQ ID NO: 34) and I-68 primer (SEQ ID NO: 35), and I-69 primer (SEQ ID NO: 36) and I-70 primer (SEQ ID NO: 37). The plasmid prepared in the above [Construction of pmi promoter-linked Fluc and preparation of plasmid] In the plasmid, the pmi promoter was replaced with each candidate promoter using EcoRI and KpnI to prepare plasmids into which each candidate promoter, Fluc, and a transcription terminator region were inserted.
[0072] [Table 3] In the table, the sequences are oriented from left to right from 5' to 3' end.
[0073] The base sequences of the primers used are shown in Table 4.
[0074] [Table 4] In the table, the sequences are oriented from left to right from 5' to 3' end.
[0075] (3) Transformation of E. coli for conjugation 200 μg / mL hygromycin instead of 50 μg / mL apramycin as antibiotic The conjugative E. coli was transformed with each of the prepared plasmids in the same manner as in Example 1, except that pGH was used as a negative control empty vector. there was.
[0076] (4) Preparation of transformed actinomycetes 200 μg / mL hygromycin instead of 50 μg / mL apramycin as antibiotic The obtained conjugative E. coli was used to transform actinomycetes in the same manner as in Example 1, except that 4 μl of 200 mg / mL hygromycin was used as the antibiotic solution instead of 20 μl of 50 mg / mL apramycin.
[0077] (5) Cultivation of transformants The transformant was cultured in the same manner as in Example 1, except that 50 mg / L hygromycin was used instead of 50 mg / L apramycin as the antibiotic.
[0078] (6) Measurement of luciferase luminescence The amount of luminescence from luciferase per unit protein amount in each transformant was calculated in the same manner as in Example 1. The results are shown in FIG.
[0079] (7) Results Although no promoters that showed luciferase activity higher than that of the pmi promoter were obtained, The upstream promoter region of the gene coding for the protein WP_003988467.1 showed relatively high luciferase activity, suggesting that it can be used as a novel promoter. However, the upstream promoter regions of the genes coding for the proteins WP_003988028.1, WP_039931923.1, and WP_003991794.1 did not show luciferase activity (data for WP_003991794.1 are not shown).
Claims
1. A vector comprising a gene of interest operably linked to a promoter, The promoter is a polynucleotide having the base sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or A vector comprising a polynucleotide which hybridizes under stringent conditions with a polynucleotide having a complementary sequence to the base sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 and has promoter activity in actinomycete cells.
2. The vector according to claim 1, wherein the polynucleotide having promoter activity is a polynucleotide having a base sequence having 90% or more identity to the base sequence of SEQ ID NO: 1, a base sequence having 90% or more identity to the base sequence of SEQ ID NO: 2, or a base sequence having 90% or more identity to the base sequence of SEQ ID NO:
3.
3. A transformed actinomycete, transformed with the vector according to claim 1.
4. The transformed actinomycete according to claim 3, which is a bacterium of the genus Streptomyces.
5. The transformed actinomycete according to claim 4, wherein the bacterium of the genus Streptomyces is Streptomyces viridochromogenes.
6. The transformed actinomycete according to claim 3 , wherein the target gene is a foreign gene.
7. A method for producing a protein, comprising culturing the transformed actinomycete according to any one of claims 3 to 6 and allowing the transformed actinomycete to accumulate a protein encoded by a gene of interest.
8. A polynucleotide having the base sequence of SEQ ID NO: 3, or A promoter comprising a polynucleotide which hybridizes under stringent conditions with a polynucleotide having a complementary sequence to the base sequence of SEQ ID NO: 3 and has promoter activity in actinomycete cells.
Citation Information
Patent Citations
Streptomycete constitutive promoter and applications thereof
CN103421778A
Method for constructing high-producing strains of genetic engineering salinomycins
CN105420266A
